183 related articles for article (PubMed ID: 36593459)
1. The effect of prophylactic chemotherapy on treatment outcome of postmolar gestational trophoblastic neoplasia.
Liu Y; Ye Y; Cheng X; Lu W; Xie X; Wang X; Li X
BMC Womens Health; 2023 Jan; 23(1):1. PubMed ID: 36593459
[TBL] [Abstract][Full Text] [Related]
2. Prevention of postmolar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment.
Uberti EM; Fajardo Mdo C; da Cunha AG; Rosa MW; Ayub AC; Graudenz Mda S; Schmid H
Gynecol Oncol; 2009 Aug; 114(2):299-305. PubMed ID: 19427681
[TBL] [Abstract][Full Text] [Related]
3. Single-dose actinomycin D: Efficacy in the prophylaxis of postmolar gestational trophoblastic neoplasia in adolescents with high-risk hydatidiform mole.
Uberti EM; Diestel MC; Guimarães FE; De Nápoli G; Schmid H
Gynecol Oncol; 2006 Aug; 102(2):325-32. PubMed ID: 16476471
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.
Wang Q; Fu J; Hu L; Fang F; Xie L; Chen H; He F; Wu T; Lawrie TA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007289. PubMed ID: 28892119
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.
Fu J; Fang F; Xie L; Chen H; He F; Wu T; Hu L; Lawrie TA
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD007289. PubMed ID: 23076934
[TBL] [Abstract][Full Text] [Related]
6. Influence of COVID-19 pandemic on molar pregnancy and postmolar gestational trophoblastic neoplasia: An observational study.
Campos V; Paiva G; Padron L; Freitas F; Pedrotti LG; Sun SY; Viggiano M; Oliveira L; Rohr L; Madi JM; Arrym TP; Oliveira P; Dos Santos Esteves APV; Junior JA; Filho JR; Elias KM; Horowitz NS; Braga A; Berkowitz RS
BJOG; 2023 Feb; 130(3):292-302. PubMed ID: 36209485
[TBL] [Abstract][Full Text] [Related]
7. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study.
Kim BW; Cho H; Kim H; Nam EJ; Kim SW; Kim S; Kim YT; Kim JH
Eur J Obstet Gynecol Reprod Biol; 2012 Jan; 160(1):100-5. PubMed ID: 22055909
[TBL] [Abstract][Full Text] [Related]
8. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
[TBL] [Abstract][Full Text] [Related]
9. A Novel Prediction Model for Postmolar Gestational Trophoblastic Neoplasia and Comparison With Existing Models.
Zhao P; Wang S; Zhang X; Lu W
Int J Gynecol Cancer; 2017 Jun; 27(5):1028-1034. PubMed ID: 28498254
[TBL] [Abstract][Full Text] [Related]
10. Postmolar choriocarcinoma: An independent risk factor for chemotherapy resistance in low-risk gestational trophoblastic neoplasia.
Strohl AE; Lurain JR
Gynecol Oncol; 2016 May; 141(2):276-280. PubMed ID: 26896825
[TBL] [Abstract][Full Text] [Related]
11. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia.
Maestá I; Nitecki R; Desmarais CCF; Horowitz NS; Goldstein DP; Elias KM; Berkowitz RS
Gynecol Oncol; 2020 May; 157(2):372-378. PubMed ID: 32037196
[TBL] [Abstract][Full Text] [Related]
13. Combined analysis of clinical features, human chorionic gonadotropin (hCG) value, and hCG ratios for early prediction of postmolar gestational trophoblastic neoplasia.
Rakprasit C; Ruengkhachorn I; Therasakvichya S; Inthasorn P; Achariyapota V; Kuljarasnont S; Khemworapong K; Jareemit N
Arch Gynecol Obstet; 2023 Apr; 307(4):1145-1154. PubMed ID: 36116082
[TBL] [Abstract][Full Text] [Related]
14. PTEN and MDM2 expression in the prediction of postmolar gestational trophoblastic neoplasia.
Lertkhachonsuk R; Tantbirojn P; Paiwattananupant K
J Reprod Med; 2012; 57(7-8):333-40. PubMed ID: 22838251
[TBL] [Abstract][Full Text] [Related]
15. Influence of hydatidiform mole follow-up setting on postmolar gestational trophoblastic neoplasia outcomes: a cohort study.
Dantas PR; Maestá I; Cortés-Charry R; Growdon WB; Braga A; Rudge MV; Berkowitz RS
J Reprod Med; 2012; 57(7-8):305-9. PubMed ID: 22838246
[TBL] [Abstract][Full Text] [Related]
16. Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia?
Sun SY; Melamed A; Goldstein DP; Bernstein MR; Horowitz NS; Moron AF; Maestá I; Braga A; Berkowitz RS
Gynecol Oncol; 2015 Jul; 138(1):46-9. PubMed ID: 25969351
[TBL] [Abstract][Full Text] [Related]
17. State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia.
Elias KM; Berkowitz RS; Horowitz NS
J Natl Compr Canc Netw; 2019 Nov; 17(11):1396-1401. PubMed ID: 31693988
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of High-Dose Vitamin A Treatment in Postmolar Patients with Low and Plateauing Serum Human Chorionic Gonadotropin Levels.
Uberti EMH; Diaz RKE; Cardoso RB; Braga A
Rev Bras Ginecol Obstet; 2020 May; 42(5):240-247. PubMed ID: 32483804
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
[TBL] [Abstract][Full Text] [Related]
20. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review.
Braga A; Maestá I; Short D; Savage P; Harvey R; Seckl MJ
BJOG; 2016 Jul; 123(8):1330-5. PubMed ID: 26444183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
